CXCR4 and lymphoma: In contrast, the FDA-approved CXCR4 antagonist AMD3100 primarily interacts with the major CXCR4 binding pocket, showing no effect on anti-inflammatory or interferon pathways but effectively mobilizing lymphoma cells from bone marrow niches into the periphery [48,49].